Compare GSK plc (GSK) vs Workiva Inc (WK) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

Workiva (WK) stock trades at $56.86, up 5.9% in the last session, reflecting strong momentum. The technical picture is bullish with price above key moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, the company has beaten earnings estimates for three consecutive quarters and shows improving revenue growth, though profitability metrics remain thin with a net margin of 1.53%. Analyst sentiment is overwhelmingly positive with an 88.9% buy rating and a $71 consensus price target.

The outlook is positive based on consistent earnings beats, strong analyst support, and projected revenue and profit growth into 2026. Key opportunities include the company's dominant position in compliance software and AI-powered platform expansion. Primary risks involve high valuation multiples (P/E of 226.6), thin current profitability, and execution pressure to meet elevated growth expectations.